Market revenue in 2021 | USD 30.4 billion |
Market revenue in 2030 | USD 52.7 billion |
Growth rate | 6.3% (CAGR from 2021 to 2030) |
Largest segment | Anti-hypertensive |
Fastest growing segment | Anti-hypertensive |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD billion |
Market segmentation | Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering drugs, Anti-depressants, Anti-psychotics, Anti-epileptics |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, Lupin, Sanofi SA, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, GlaxoSmithKline, Pfizer Inc, Apotex Inc., Viatris Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to branded generics market will help companies and investors design strategic landscapes.
Anti-hypertensive was the largest segment with a revenue share of 15.79% in 2021. Horizon Databook has segmented the China branded generics market based on alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.
China is expected to grow at a moderate to slow rate over the forecast period. Increase in healthcare expenditure for pharmaceuticals and government initiatives that encourage generic players to enter the regional market are among some of the factors anticipated to drive market growth.
Furthermore, the government supports R&D of generics to enhance the quality and efficacy of products. In April 2018, the State Council passed a circular on Opinions Concerning Reforms of Policies to Improve the Supply and Utilization of Generics, which may have a positive impact on the market dynamics of generic manufacturers.
China branded generics market is a price-sensitive market. Consumers favor the lowest available price over brand loyalty. Thus, market players should embrace a promotional and operational strategy that keeps their drug prices low to compete with other generic brands.
Horizon Databook provides a detailed overview of country-level data and insights on the China branded generics market , including forecasts for subscribers. This country databook contains high-level insights into China branded generics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account